Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
about
Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisEfficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Urgency to treat patients with chronic hepatitis C in Asia.Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVDirect-acting antiviral agents against hepatitis C virus and lipid metabolism.Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b.Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.
P2860
Q28077287-31A0709F-1839-4752-90CE-3B54F11DF4D3Q33805907-2A315AF1-2772-4DF0-AA61-E085C1164595Q39016874-BD1F7389-4942-4F2F-8BE5-1379639E8381Q39049155-45744AFD-3346-42E2-89F7-79BC841B9398Q40080544-327C662E-D519-4152-AB07-9E78D15B7472Q40086558-E3BBB3A5-33FF-4C9B-9F30-0A4932FD107CQ40217467-A96FDD6F-FCE0-4A78-A977-E57D68E8D547Q40228687-11E0A3DD-1D14-4C8B-858B-85D9FBAA1110Q42349373-D7606246-70A6-4F10-90FC-955E5E2CAB79Q45325544-45ADFBD6-48FA-4029-8D4B-2B7C00591C67Q47121490-7CC5BC38-3EE7-4B78-A620-925C4B4CBDDEQ47657221-90E59CFB-A68D-4AB6-97A8-921C4C6E14C5Q50045992-28823345-3EF7-41C1-9774-C065D76E01D2Q54254997-B6214C3B-790F-48A3-84DC-E7BB9F3D58E8
P2860
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Daclatasvir plus Asunaprevir T ...... e 1-Infected Patients in Japan
@en
type
label
Daclatasvir plus Asunaprevir T ...... e 1-Infected Patients in Japan
@en
prefLabel
Daclatasvir plus Asunaprevir T ...... e 1-Infected Patients in Japan
@en
P2093
P2860
P356
P1476
Daclatasvir plus Asunaprevir T ...... e 1-Infected Patients in Japan
@en
P2093
Eiichiro Suzuki
Fumio Imazeki
Makoto Arai
Masato Nakamura
Osamu Yokosuka
Reina Sasaki
Shin Yasui
Shingo Nakamoto
Tatsuo Kanda
P2860
P304
P356
10.7150/IJMS.15519
P407
P577
2016-05-12T00:00:00Z